Zhihui Duan*


Department of Respiratory and Critical Care Medicine Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, 010050, China


This study aimed at investigating the expression and predictive value of efficacy of PD-1 and PD-L1 in lung cancer patients after radiotherapy. Totally 118 cases of lung cancer patients admitted to our hospital from March 2019 to March 2021 were included in the research group (RG), and 110 healthy subjects underwent physical examination simultaneously were included in the control group (CG). Concentrations of PD-1 and PD-L1 in peripheral blood of patients in both groups were detected before radiotherapy (T0), radiotherapy for 2 weeks (T1), radiotherapy for 4 weeks (T2), and radiotherapy for 6 weeks (T3), respectively. And the clinical significance of PD-1 and PD-L1 was analyzed. Both PD-1 and PD-L1 decreased in small-cell lung cancer (SCLC) (P<0.050) and gradually decreased after treatment (P<0.050). ROC analysis exhibited that PD-1 and PD-L1 had good diagnostic effects in predicting occurrence, efficacy and toxic and side effects of lung cancer. In conclusion, both PD-1 and PD-L1 increased in SCLC. It was detected that PD-1 and PD-L1 had significant predictive value for the occurrence of small-cell lung cancer, radiotherapy efficacy and toxic and side effects. PD-1 and PD-L1 might be potential diagnosis and treatment indicators for SCLC in the future.


PD-1, PD-L1, small-cell lung cancer, clinical efficacy.